… of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. …
the study until its termination, but no further reductions in triamcinolone dosage were attempted. …

… reductions: SGRQ score change of 4 points and FEV 1 change of 100 mL. The thresholds
for clinically important relative risk reductions … important absolute risk reductions were based …

… inhaled corticosteroids will, in general, have substantially worse outcomes than those not
withdrawn. Nevertheless, we cannot advocate the withdrawal of inhaled corticosteroids … risk of …

… withdrawal of inhaled glucocorticoids, the risk of exacerbation would be similar to that with
continued use of inhaled glucocorticoids … conducted the Withdrawal of Inhaled Steroids during …

… We report the first randomised placebo-controlled study of withdrawal of long-term inhaled
corticosteroids in patients with COPD recruited in primary care. Risk of COPD exacerbation …

… included a minimum 6-month ICS-free period and therefore could not specifically identify
the immediate increased risks of ICS- withdrawal within this study, and therefore direct …

… the effect of discontinuation of inhaled corticosteroids, we … subjects who discontinued inhaled
corticosteroids within three, six… who used inhaled corticosteroids without interruption during …

… to outweigh the risks, especially when lower ICS doses are employed. Given that the data
on ICS withdrawal in COPD are scarce and conflicting, we argue that using reduced doses of …

… We conclude that the withdrawal of ICS, in COPD patients at low risk of exacerbation, can
be safe provided that patients are left on maintenance treatment with long-acting …

… Interestingly, withdrawal of inhaled corticosteroids in this study resulted in a 2-fold rise in
the rate of exacerbations among those with an FEV 1 <50% of predicted compared with the …